# EDGAR Filing Document

**Accession Number:** 0001583771
**File Stem:** 0001493152-26-016557
**Filing Date:** 2026-4
**Character Count:** 5145
**Document Hash:** 6e604ee9bc95de42fcb35dac300ba6dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-016557.hdr.sgml**: 20260414

**ACCESSION NUMBER**: 0001493152-26-016557

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260413

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260414

**DATE AS OF CHANGE**: 20260414

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hepion Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001583771
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462783806
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36856
- **FILM NUMBER:** 26861153

**BUSINESS ADDRESS:**
- **STREET 1:** 34 SHREWSBURY AVE.
- **STREET 2:** SUITE 1D
- **CITY:** RED BANK
- **STATE:** NJ
- **ZIP:** 07701
- **BUSINESS PHONE:** 732-902-4000

**MAIL ADDRESS:**
- **STREET 1:** 34 SHREWSBURY AVE.
- **STREET 2:** SUITE 1D
- **CITY:** RED BANK
- **STATE:** NJ
- **ZIP:** 07701

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ContraVir Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130806

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the** 

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 13, 2026**

**Hepion Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36856** | **46-2783806** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission<br> File Number) | (IRS<br> Identification No.) |

---

**34 Shrewsbury Ave., Suite 1D**

**Red Bank, NJ 07701**

(Address of principal executive offices)

**(732) 902-4000**

(Registrant's telephone number, including area code)

**55 Madison Ave., Suite 400-PMB# 4362** 

**Morristown, NJ 07960**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading Symbol(s)** | **Name of each exchange on which registered:** |
| Common Stock, par value $0.0001 per share | HEPA | OTC QB |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.** |

---

Previously on March 16, 2026, Hepion Pharmaceuticals, Inc. (the "Company") disclosed that Dr. Kaouthar Lbiati, CEO resigned as CEO for personal reasons. On April 13, 2026 (the "Separation Date"), the Company entered into a separation agreement with Dr. Lbiati pursuant to which, among other things, she will be paid (i) $225,000, (ii) $30,625 representing the pro-rata portion of her potential cash bonus and (iii) reimbursement of her COBRA payments for 6 months.

Further, pursuant to the separation agreement, Dr. Lbiati agreed to a general release and confidentiality

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

The information set forth above under Item 1.01 is incorporated herein by reference.

On April 13, 2026, Dr. Lbiati resigned as a director of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: April 14, 2026 | **Hepion Pharmaceuticals, Inc.** | **Hepion Pharmaceuticals, Inc.** |
|  | By: | */s/ Gary Stetz* |
|  |  | Gary Stetz |
|  |  | Interim Chief Executive Officer |

---